Eli Lilly Q4 Earnings: Strong Demand For Mounjaro But Prices Dip, Forecasts Over 30% Jump In 2025 Sales On Newer MedicinesBenzinga • 02/06/25
Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expectedCNBC • 02/06/25
Eli Lilly Earnings Top, 2025 Guidance Strong, But Weight-Loss Drug Sales MissInvestors Business Daily • 02/06/25
Eli Lilly forecasts 2025 profit largely above estimates on launch of weight-loss drug in new marketsReuters • 02/06/25
Eli Lilly Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate AnalystsBenzinga • 02/06/25
Curious about Lilly (LLY) Q4 Performance? Explore Wall Street Estimates for Key MetricsZacks Investment Research • 02/03/25
With Zepbound Not Matching Expectations, Should Investors Give Up on Eli Lilly?The Motley Fool • 02/02/25
FDA Approval of Eli Lilly's Omvoh for Crohn's Disease Adds a New Option, but Uptake May be Hampered by US Gastroenterologists' Brand Preferences Among the IL-23 Class, According to Spherix Global InsightsGlobeNewsWire • 01/31/25